Theradaptive
1 known investors
Theradaptive develops engineered protein therapeutics with improved targeted delivery to enhance efficacy and reduce side effects across clinical indications including orthopedics, soft tissue repair, and targeted chemotherapy. The company creates material binding variants of recombinant proteins to address delivery limitations in treating tissue loss conditions.
BiotechDeep TechMedical Devices
Investors · 1
In the news
- A Look At Alphatec Holdings (ATEC) Valuation After 2026 Guidance And Theradaptive Partnership Newsfinance.yahoo.com · 2026
- Alphatec Holdings, Inc. and Theradaptive Enter Strategic Partnership for Breakthrough Regenerative Technology in Spinal Fusion | MarketScreenermarketscreener.com · 2026
- Chronicles in Leadership: Luis Alvarez, CEO of RegenerativeMedicine Biotech Theradaptive | Newsnews.biobuzz.io · 2025
- Frederick Maryland’s Theradaptive Raises $26M Series A to Advance Regenerative Therapeutics | Newsnews.biobuzz.io · 2025
- Theradaptive Secures Landmark Funding from Maryland Stem Cell Research Fund (MSCRF) to Support Human Clinical Trialsprnewswire.com · 2024
- Theradaptive Closes $6.2 Million Series A Investment Round | Orthopedics This Weekorthotw.com · 2021